Sofiva GenomicsLtd Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Sofiva GenomicsLtd's earnings have been declining at an average annual rate of -15.7%, while the Healthcare industry saw earnings growing at 6.8% annually. Revenues have been declining at an average rate of 1.1% per year. Sofiva GenomicsLtd's return on equity is 4%, and it has net margins of 5.2%.
Belangrijke informatie
-15.7%
Groei van de winst
-15.9%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 9.1% |
| Inkomstengroei | -1.1% |
| Rendement op eigen vermogen | 4.0% |
| Nettomarge | 5.2% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Some Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On Capital
Apr 14
Estimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)
Mar 18Sofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its Dividend
Feb 24Should Weakness in Sofiva Genomics Co.,Ltd.'s (GTSM:6615) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jan 27Our Take On The Returns On Capital At Sofiva GenomicsLtd (GTSM:6615)
Jan 07
A Look At The Intrinsic Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)
Dec 15Read This Before Buying Sofiva Genomics Co.,Ltd. (GTSM:6615) For Its Dividend
Nov 24Opbrengsten en kosten
Hoe Sofiva GenomicsLtd geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 478 | 25 | 132 | 8 |
| 31 Mar 24 | 475 | 20 | 134 | 9 |
| 31 Dec 23 | 467 | 12 | 136 | 10 |
| 30 Sep 23 | 472 | 34 | 135 | 12 |
| 30 Jun 23 | 473 | 31 | 134 | 13 |
| 31 Mar 23 | 483 | 33 | 135 | 11 |
| 31 Dec 22 | 496 | 43 | 135 | 10 |
| 30 Sep 22 | 501 | 37 | 135 | 8 |
| 30 Jun 22 | 506 | 49 | 135 | 7 |
| 31 Mar 22 | 510 | 62 | 132 | 8 |
| 31 Dec 21 | 508 | 57 | 131 | 11 |
| 30 Sep 21 | 507 | 53 | 130 | 12 |
| 30 Jun 21 | 505 | 44 | 126 | 13 |
| 31 Mar 21 | 494 | 33 | 125 | 12 |
| 31 Dec 20 | 489 | 35 | 122 | 10 |
| 30 Sep 20 | 489 | 37 | 121 | 8 |
| 30 Jun 20 | 497 | 48 | 123 | 7 |
| 31 Mar 20 | 506 | 59 | 123 | 8 |
| 31 Dec 19 | 509 | 63 | 123 | 8 |
| 30 Sep 19 | 504 | 61 | 119 | 8 |
| 30 Jun 19 | 486 | 51 | 112 | 9 |
| 31 Mar 19 | 469 | 49 | 107 | 9 |
| 31 Dec 18 | 459 | 47 | 101 | 9 |
| 30 Sep 18 | 451 | 46 | 100 | 8 |
| 30 Jun 18 | 446 | 48 | 101 | 6 |
| 31 Mar 18 | 438 | 45 | 97 | 6 |
| 31 Dec 17 | 424 | 45 | 95 | 4 |
| 30 Sep 17 | 410 | 48 | 91 | 4 |
| 30 Jun 17 | 398 | 49 | 87 | 6 |
| 31 Mar 17 | 388 | 45 | 84 | 6 |
| 31 Dec 16 | 384 | 43 | 83 | 7 |
| 30 Jun 16 | 373 | 33 | 80 | 9 |
| 31 Mar 16 | 356 | 25 | 79 | 8 |
| 31 Dec 15 | 344 | 16 | 78 | 8 |
| 31 Dec 14 | 295 | 23 | 66 | 0 |
| 31 Dec 13 | 154 | -23 | 40 | 0 |
Kwaliteitswinsten: 6615 has high quality earnings.
Groeiende winstmarge: 6615's current net profit margins (5.2%) are lower than last year (6.6%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 6615's earnings have declined by 15.7% per year over the past 5 years.
Versnelling van de groei: 6615's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 6615 had negative earnings growth (-19%) over the past year, making it difficult to compare to the Healthcare industry average (3.6%).
Rendement op eigen vermogen
Hoge ROE: 6615's Return on Equity (4%) is considered low.